Development and validation of clinical scales for defining RBD severity in participants of the North American Prodromal Synucleinopathy (NAPS) consortium
Objective: The objective of this study is to assess the internal validity of the REM Sleep Behavior Disorder (RBD) symptom severity scale (RBDSSS) and its…Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease
Objective: To evaluate long-term deutetrabenazine safety on motor, psychiatric, and cognitive measures in participants with chorea associated with Huntington disease (HD). Background: Deutetrabenazine, a vesicular…Subclinical inflammation and Parkinson’s disease
Objective: To investigate subclinical inflammation in individuals with early drug-naive Parkinson’s disease (PD). Background: Neutrophil-to-lymphocyte ratio (NLR) is used as a marker of subclinical inflammation.…Development of quantitative tools for in-home clinical assessment of people with Parkinson’s disease
Objective: To develop telehealth digital data collection methods for evaluation of multi-modal function in people with Parkinson’s Disease (PwPD) and develop biomedical informatics tools for…Qualitative Interviews With Children/Adolescents With Dyskinetic Cerebral Palsy (DCP) and Their Caregivers
Objective: To capture input from children/adolescents with DCP and their caregivers on the content validity of the Movement Disorders–Childhood Rating Scale (MD-CRS). Background: DCP is…Caregiving people with Parkinson’s disease (PPD)
Objective: To show results form a study on caregiving PPD from a relational perspective. Background: Caregiving people with chronic neurological diseases like PPD can lead…Translation and validation of two Parkinson’s disease specific burden questionnaires from German into French.
Objective: The study purpose was to translate the questionnaires and to evaluate their internal consistency and temporal stability in a French study population, composed of…Validation of biomarkers in Huntington’s disease to support the development of disease-modifying therapies: a systematic review and critical appraisal scheme
Objective: To review studies for disease progression biomarkers published in HD and evaluate their methodological quality in a standardized manner. Background: Huntington disease (HD) is a fatal autosomal dominant neurodegenerative condition that starts to manifest clinically around the 4th decade of life. There are promising novel genetic-based therapies under development intended to modify the disease trajectory. Valid…The impact of gender identity and gender role orientation on health-related quality of life in people with Parkinson’s disease.
Objective: To assess the associations of gender identity and gender role orientation with health-related quality of life (HRQoL) among persons with Parkinson’s disease (PD). Background:…Relationship of satisfaction and adherence in remote digital monitoring: Results from a clinical drug trial in early Parkinson’s disease
Objective: To investigate satisfaction with daily remote monitoring with a digital health technology tool (DHTT) in individuals with early Parkinson’s disease (PD) and the relationship…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 32
- Next Page »